COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

被引：0
|
作者：
Guzauskas, Gregory [1 ]
Wang, Bruce C. M. [2 ]
Pollom, Erqi [3 ]
Stieber, Volker W. [4 ]
Garrison, Lou [1 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] Elysia Grp, New York, NY USA
[3] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
[4] Novant Hlth Forsyth Med Ctr, Dept Radiat Oncol, Winston Salem, NC USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HOUT-18
引用
收藏
页码：116 / 117
页数：2
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, G. F.
    Wang, B. C. M.
    Pollom, E. L.
    Stieber, V. W.
    Kinzel, A.
    Proescholdt, C.
    Garrison, L.
    NEURO-ONCOLOGY, 2018, 20 : 254 - 254
  • [2] Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone
    Guzauskas, G. F.
    Pollom, E.
    Wang, B. C. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E244 - E245
  • [3] COST-EFFECTIVENESS ANALYSIS OF ADDING TUMOR TREATING FIELDS THERAPY TO TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ONLY IN PATIENTS WITH GLIOBLASTOMA IN FRANCE
    Guzman, Nino de Rivera J.
    Borgel, J.
    Chavez, G.
    Puc, C.
    Indukuri, N.
    Koh, C. Y. C.
    Poignant, P.
    Duteil, E.
    Gerves-Pinquie, C.
    Leproust, S.
    VALUE IN HEALTH, 2023, 26 (12) : S121 - S121
  • [4] Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
    Stupp, Roger
    Taillibert, Sophie
    Kanner, Andrew A.
    Kesari, Santosh
    Steinberg, David M.
    Toms, Steven A.
    Taylor, Lynne P.
    Lieberman, Frank
    Silvani, Antonio
    Fink, Karen L.
    Barnett, Gene H.
    Zhu, Jay-Jiguang
    Henson, John W.
    Engelhard, Herbert H.
    Chen, Thomas C.
    Tran, David D.
    Sroubek, Jan
    Iran, Nam D.
    Hottinger, Andreas F.
    Landolfi, Joseph
    Desai, Rajiv
    Caroli, Manuela
    Kew, Yvonne
    Honnorat, Jerome
    Idbaih, Ahmed
    Kirson, Eilon D.
    Weinberg, Uri
    Palti, Yoram
    Hegi, Monika E.
    Ram, Zvi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (23): : 2535 - 2543
  • [5] A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma
    Alexiades, Nikita
    McKhann, Guy M., II
    NEUROSURGERY, 2018, 82 (05) : E115 - E116
  • [6] Maintenance Therapy with Tumor-Treating Fields plus Temozolomide vs Temozolomide alone for Glioblastoma. A Randomized Clinical Trial
    Gervais, C.
    Feuvret, L.
    ONCOLOGIE, 2016, 18 (05) : 355 - 357
  • [7] Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
    Stupp, Roger
    Taillibert, Sophie
    Kanner, Andrew
    Read, William
    Steinberg, David M.
    Lhermitte, Benoit
    Toms, Steven
    Idbaih, Ahmed
    Ahluwalia, Manmeet S.
    Fink, Karen
    Di Meco, Francesco
    Lieberman, Frank
    Zhu, Jay-Jiguang
    Stragliotto, Giuseppe
    Tran, David D.
    Brem, Steven
    Hottinger, Andreas F.
    Kirson, Eilon D.
    Lavy-Shahaf, Gitit
    Weinberg, Uri
    Kim, Chae-Yong
    Paek, Sun-Ha
    Nicholas, Garth
    Burna, Jordi
    Hirte, Hal
    Weller, Michael
    Palti, Yoram
    Hegi, Monika
    Ram, Zvi
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (23): : 2306 - 2316
  • [8] TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Nicholas, Garth A.
    Hirte, Holger
    Easaw, Jacob
    Muanza, Thierry
    Roberge, David
    Mathieu, David
    Pitz, Marshall
    NEURO-ONCOLOGY, 2017, 19 : 138 - 138
  • [9] Combining radiation plus temozolomide in glioblastoma patients older than 65 years of age
    Straube, Christoph
    Combs, Stephanie E.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (06) : 510 - 512
  • [10] Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
    Guzauskas, Gregory F.
    Pollom, Erqi L.
    Stieber, Volker W.
    Wang, Bruce C. M.
    Garrison, Louis P., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 1006 - 1013
12345